Lead Product(s): Plasminogen
Therapeutic Area: Genetic Disease Product Name: Ryplazim
Highest Development Status: Approved Product Type: Large molecule
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 23, 2021
This acquisition would include the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through its subsidiaries, Prometic Bioproduction Inc., the Company’s plasma-derived therapeutics manufacturing facility (“PBP”), and Prometic Biotherapeutics Inc.